<SEC-DOCUMENT>0001144204-12-050537.txt : 20120911
<SEC-HEADER>0001144204-12-050537.hdr.sgml : 20120911
<ACCEPTANCE-DATETIME>20120911123356
ACCESSION NUMBER:		0001144204-12-050537
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20120911
DATE AS OF CHANGE:		20120911
EFFECTIVENESS DATE:		20120911

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		121085053

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>v323440_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>

     <HEAD>

          <TITLE></TITLE>

     </HEAD>

<BODY>

<DIV style="text-align: center; min-width: 708">


<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">UNITED STATES<BR> SECURITIES AND EXCHANGE COMMISSION<BR> Washington, D.C. 20549 </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCHEDULE 14A<BR>(RULE 14a-101)<BR> INFORMATION REQUIRED IN PROXY STATEMENT </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCHEDULE 14A INFORMATION </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Proxy Statement Pursuant to Section 14(a) of the<BR> Securities Exchange Act of 1934 </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 180px; text-align: left">Filed by the Registrant</TD>

          <TD STYLE="text-align: left"><FONT STYLE="font-family: wingdings">x</font> </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 180px; text-align: left">Filed by a Party other than the Registrant</TD>

          <TD STYLE="text-align: left"><FONT STYLE="font-family: wingdings">o</font> </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Check the appropriate box: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Preliminary Proxy Statement </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B> </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Definitive Proxy Statement </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">x</font></TD>

          <TD STYLE="text-align: left">Definitive Additional Materials </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Soliciting Material under &sect;240.14a-12 </TD>

</TR>

</TABLE>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 18pt; line-height: 20pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SYNTHETIC BIOLOGICS, INC. </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Name of Registrant as Specified In Its Charter) </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 252px; height: 1pt"></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Payment of Filing Fee (Check the appropriate box): </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">x</font></TD>

          <TD STYLE="text-align: left">No fee required. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Title of each class of securities to which transaction applies:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Aggregate number of securities to which transaction applies:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Proposed maximum aggregate value of transaction:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Total fee paid:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Fee paid previously with preliminary materials.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><FONT STYLE="font-family: wingdings">o</font></TD>

          <TD STYLE="text-align: left">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Amount Previously Paid:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Form, Schedule or Registration Statement No.:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Filing Party:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Date Filed:</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="logo_synthetic-bio.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">September 11, 2012 </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To Our Shareholders, </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The past year has been one of determination, transition and most important, revitalized dedication to the development of synthetic biologics and innovative medicines for unmet medical needs. During this time we have concentrated our efforts on becoming a leader in the emerging field of synthetic biologics, strategically realigning our existing clinical trial pipeline, and strengthening and expanding our management team. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Focused on Synthetic Biologics </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Determined to be at the forefront of the synthetic biology movement, we entered into two worldwide exclusive channel collaborations with Intrexon Corporation, a privately-held synthetic biology company. Pursuant to these collaborations, we will have access to Intrexon&#146;s comprehensive suite of proprietary technologies for the development of new therapies for serious diseases that currently have limited or no treatment options. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under our most recent collaboration, we intend to develop fully human monoclonal antibodies (mAbs) for the treatment of infectious diseases &#150; a field of medicine that is in crisis due to the rapid decline of effective treatment options. Initially, we will target three large-market infectious disease indications that have become increasingly resistant to antibiotics and other drugs. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the accompanying 2012 proxy statement, we are seeking shareholder approval to issue common stock in connection with the Intrexon infectious disease collaboration. With such approval, we look forward to utilizing Intrexon&#146;s competencies for the development of a series of fully human mAbs to combat the worldwide toll on human life caused by infectious diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are also pursuing the development of a synthetic DNA-based therapy to treat pulmonary arterial hypertension (PAH) in collaboration with Intrexon. We are evaluating several approaches to deliver therapeutically relevant levels of prostacyclin through the expression of prostacyclin synthase (PGIS) with the expectation of improved patient efficacy and safety outcomes compared to existing PAH treatments. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Advancing Clinical Trial Programs </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While our primary focus targets the field of synthetic biologics, we continue to advance our existing clinical programs for the development of treatments for multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our investigational oral estriol drug, Trimesta<sup>TM</sup>, a natural hormone, similar to estrogen that is produced during pregnancy and has been scientifically documented to reduce symptoms of certain autoimmune diseases, including MS. Trimesta<sup>TM</sup> is currently being evaluated in two separate Phase II MS clinical trials. One trial is studying the ability of Trimesta<sup>TM</sup> to reduce MS relapse rates in women. This trial completed enrollment of 164 patients earlier this year, and patients will each be dosed and monitored for two years. The second trial initiated enrollment of female patients to investigate the
effect of Trimesta<sup>TM</sup> on cognitive dysfunction related to MS. If successful, Trimesta<sup>TM</sup> can potentially offer patients an oral, disease-modifying treatment to reduce the debilitating effects of MS. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Utilizing our position as a leader in the field of zinc biology, we have transitioned our efforts to target the devastating progressive neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&#146;s disease. Based on a study conducted by the PNA Center for Neurological Research which demonstrated dramatic results in ALS using oral high dose zinc, we expect to initiate a Phase II clinical trial during 2013. This trial is designed to evaluate our proprietary, gastroretentive, sustained-release, oral zinc-based drug candidate, AEN-100, in the treatment of ALS. It has often been theorized that there
is too little available zinc in the brain of people suffering from ALS, and in the absence of available zinc, neurons burn out through a process called excitotoxicity, and are unable to perform necessary repair functions. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Strengthening and Expanding the Management Team </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe that the opportunity to develop new therapeutics holds so much promise that, in addition to our collaborations with Intrexon and support from its CEO, R.J. Kirk, we have added key members to our team. Over the past eight months we have expanded and strengthened the management team to include: Evan Ballantyne, Chief Financial Officer, formerly the CFO of Clinical Data; Carol Reed, M.D., Sr. Vice President of Clinical &amp; Regulatory Affairs, formerly the CMO of Clinical Data; John Monahan, Ph.D., Sr. Vice President of Research &amp; Development, who was the formerly the founder and CEO of gene therapy company
Avigen; and Mike Kaleko, M.D., Ph.D., Scientific Director, who was formerly the co-head of gene therapy at Novartis. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Future </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although our initial efforts in the field of synthetic biology are focused on the development of fully human mAbs for infectious diseases and a synthetic DNA-based therapy for PAH, we intend to evaluate additional opportunities to enhance our pipeline in the near-term. At the same time, we intend to move our MS and ALS clinical programs forward. We are aware that there is much to be done, and our team is dedicated to reaching our goals of developing synthetic biologics and innovative medicines for unmet medical needs and creating additional value in our Company. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On behalf of our team, board directors, clinical investigators, patients and their families, thank you for your continued support. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sincerely, </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="sig_jriley.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Jeffrey Riley<BR> Chief Executive Officer </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>This letter includes forward-looking statements on Synthetic Biologics&#146; current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as &#147;may,&#148; &#147;should,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements
regarding our plans for our enhanced pipeline and clinical trials. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics&#146; forward-looking statements include, among others, a failure of Synthetic Biologics&#146; product candidates to be demonstrably safe and effective or successfully commercialized, our ability to obtain additional synthetic biologic programs, a failure to initiate clinical trials and if initiated a failure to achieve the desired results, a failure to obtain regulatory approval for the company&#146;s products or to comply with ongoing regulatory requirements and other factors described in Synthetic Biologics&#146; report on Form 10-K/A for the year ended December 31, 2011, and any other filings with the SEC. The
information in this letter is provided only as of the date written, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this letter on account of new information, future events, or otherwise, except as required by law.</I> </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR STYLE="width: 708px; height: 2px; text-align: center">



</DIV>

</B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B>

</I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>line.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 line.gif
K1TE&.#EA`0`!`(```````/___R'Y!```````+``````!``$```("1`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_synthetic-bio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_synthetic-bio.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```&_```&<(``"`U```FU/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`+P#^`P$1
M``(1`0,1`?_$`0T```("`P$!`0`````````````(!PD%!@H$`P$!`0$!``(#
M`0$````````````!`@4'!`8(`PD0``$$`@$#`0<"!P````````4#!`8'``(!
M$#<(0#`1$A,4%A=0%2`Q(S48*#@1``$$``4"`@8$"`<1``````,!`@0%$1(3
M%`8`%2$B$#$C)+8'03*%%E%Q-;5VAL:'0E*RI=4F-B!`\&&!H4.#-(2T)96F
MUD>W$@`!`@,%`P@'"0`````````!$0(A$@,`,4%1!$`B$_!A<8&1H3(%$"!0
MT4)B(['!X5*2LC,4%1,!``("`@$$`0('`0```````0`1(3$005$@87&!\#!`
M4)&AL<'1\>'_V@`,`P$``A$#$0```;F[-4LUWH#ND_6YGZ/]#8WB?5?1,@D-
M59ZGC,,7=YM-.I#ITG8O-+N;B88"WW-BFQ4R':S!XS0B>R5HBFL,-!#C7+DX
MW]P-#\CE%$YWWAT>`Z]V;\?%K\JH_49^&YEHLW.BG%Y^M1Q8C6KBLU.K`2ZM
M:-Q,R,/%IF;0GN7%9M">H^T719JIUD.$S//#;WSW.`&H;Y&I7UKZAN9]B^3:
M@M0*RZZ9\7F8W.K'%YL-QB(7>KBLU.K`F.6'+$ZIK8GN5Q(H3W+BLVG74UL>
MF*V*Z=O7?%17XI\5F^_>1G_O#?K\BQ5S'`<]O3O]0NE+L;^=&E?IX:C5*XP\
M+Q360G5-!"\5/<::8<V4\1&U:T>P92(<J8XA"LQ"\4T$3>8/P_R4[IKBETZ[
M\'3_`#/%A[^FOQ>SOK??]IG2_P!!U?V24K[16Q5D\*G2766^YJ=5,43&5X5[
M"P.*V*S!8?"=4XL+N(MJ6XYJOU4U9T"YH?AA$^QEE`````````````````/_
MV@`(`0$``04",R?EHY;-Y&4V7A4IU7WYLD)J+LL>LX25272Z7?9[NN@D?TOR
M?-XO<DVC3M_,[7K>9&[0CXBO:^)6?9<S#VO888G%Y(,EX%A,[0*NWY&\!303
M(K@/X6D5P`,\;S)@Y!_)R12`!DMF<P;5@P(W@5:?[`8X<7PT;L)G:!5VR(W`
M*`4!.CBTHG-X3:;&RNU^P]H$\@Y&2K\5Q\U9-/1'3H<C8J0(HN#E;%0Y9H<&
MY?M:GI\,`V'959N`5XQ0V6OV"LYG$>3!/8/2U;_CV,Q&,NY@=HJPU(!)J![M
MW]VD\3<\LL@5SRBN@]A6E(+*R:=I(A?<PA<=BODA.#DHL3M_0/=N_NTD9_LO
MBN"'O#9%@T*C_P``U)A!O]O$@IEH0;]301@=9UI.2,6L3/)-[.(^8KZ]HB1B
ML\)10O)H8P=BH?7?<#*![M^1M:;BB=`]V[^[2>)N>66>+?;_`,LLFG:2L;[A
M\+@_^4E?Y8G;^@>[=_=I*;BWWH^K*;N*MF<^\D8^;B@:).R47D8?8V*>I$`[
MD38#-7$%T'262241T,+X;%7YYBZ^N928C#VS0IXTUJ0<1*EJ]AZBAD.B3'4C
M6`HAD*@=-MBQ@.,D`QA655P%V?`"90)B<`B4&R>1&!2-I#HS%8L'ED`B4YPY
M655I1UO15..V_P"`:DPOR$>)@*AKN+ECX`3*!,(A571XQ+JJ@LVW8>,E<,W:
M;BMUHKA`:P*MCE:.D,61EH!5:Q2NK597:2.JFJ7XB>>0;Y$;(O'+11*O<DW_
M`$WEW_N'XK@ZD%*VYE_=I(G/XE.>ET\1U"6T2W;H[Y?7`U`[XV?)^S\FG=O+
M8;GG==5X_K)6>Y<[-N^K.*O6Z$=ZK+O=,15<[^L__]H`"`$"``$%`NA".R/Z
MQCM-&+[9IM[OY>O35W3Y_IN]%--D]_9\YQ[4D02%L1L@$EM>O&V^N?NRZR_L
M^<XZ<>S)L]G[(L`=#51,V;K\)*I+Z8V'.WNY08^$DM>?BU]2NW1<IDH<@KG`
M4R.WT<G>=`I\*_2D!CCW?K/_V@`(`0,``04"Z-)"(^F4^TWZ:PE;37GCG7GU
MS9XNUYV2;%D%DMT%?5>[GC^!JZ5:*R",(.0?J5D_FIIN-M>?BXZN33`5Q&)-
M')7$7"/T[CU.^FJG'*"J><K*:9R^T]Q5B3^IB(3;X/UG_]H`"`$"`@8_`O0^
MKY7K?H5-XSO>UTUQ_C$I$`D&H$:B-4TJ&N:VOY=/38YX+2C7.:"\>&JK1>7@
MB]Q41LM(S"R&_;]VRW5>5_OL6.O&U/U]</=2IHH;$Q(&)&>=UF_U*S>*[X#N
MO5%(E-Z8EJM@4)3U-PH;,T^I16JTG-RWW=7?S;4[2-,I?+'H<">X6<7MW5/1
MTM.(_;CC:3S8"C4`\39BTQNEBYL$S!C=`6%6@YKZ1Q!4=H]#:5)CDJ*AB`@@
M3-S<V,+TL[0UE=J(.!;-O+&9JA3BOS`C"P=$*-JX5=H<SGY0/.(V-70E'Y'K
MQ[+XYOLY]'B,(;>U1"^]L$Z^FW!-:K),OCC^I9DYE3%%LS3:*N)F,8)7[K\@
M(H''`R3!>D6?Y=1#@]4<3"'RXQSN2Y05]M?_V@`(`0,"!C\"]#*6NT=+B,$H
MEIM<);_C=-B5B5*N538FF#0U1F-Y;G",U,`Y`C`!+K<2@148F'*/;U60W[>M
M,[N6%N+21NI')#F,C^(L:53Q#;Q5IYQ$4=S%$AWY$&W^UY?.G#;6:UR;M(MF
M<V^]#,2KO`&MB27;26#'WV%"O!V!S]1VIK5*<]`M5NZ\S&+6EA59DN<$(4G=
M6U/SS3\*AY46FD^G4-,"B09#2>AE`.[("DU-[#*)DL_3S,?(\MF:5:Y"BM.+
M3>#B-JE>%%OH%6_E/W'[+;['CO';;Q'OM5U=>@]Q>][W&G%@"JYT)BUL83I#
MHM3\TK.9P2U6-$<QO8!,KYKY2TCVU__:``@!`0$&/P)L&L&*5*:_`[B9G!&O
MC[%,CQYBM_AKCE9AAZ\<J%)8RF(W*-VW*D4;47S>;1TAN>Q7>;!CUP_R=&)"
MY/,:V0]#%4EM/$1YLC!*Y^WC9"8#$U$7!,&HC?4G1E:X-W'CQV""A0CF9W8"
M1A/=70[B05KO*YSD=]+EQ^MT^'>P3\>D-.X"/._=0D<A`@1DB2T("PBZI'8Z
MPF#8UF+GHOAT,P2,,$S&%$43VD$41&HYA!O:JM>Q[5Q14\%3TP@5$?->\BWP
M:Z:5HR1*L<%L7=S7A?FW,QN^'MQN:HLV+B8HS2+-ON/7G*["+W*1'DEC\P%3
MQQSL@9A@`KR7%<..%@YC%:T0FA:BY6X88)/HN5VW)9]1*[C5W0)$HB<KI321
MI!/.I;2Q1\Z!<5#A9A`*_;ZB.16L>[5:6!:<KN)MEQ^8S7A3[VQNJ2P"8###
MU8TB5E/#GP9+7)B@I`D>B^R,WRC^88_?8,V'%+5P$EPA2YMA-\@ZESVG.%DR
M&9'I+:-3/CM`9<K]-4Z#5MYQRL4<IG6]^:-R6=6,AT[9@4L7U\8+UBA,Y931
M1@B`HF$>WRM$URMAV8^77U@L,R$6#<6]E9UDMF"L)'F0I,MPRA*-RIX92,^L
MQS7HUR5O(Z=QG5]F%Q`I($H)`GB,2-)CG&JN1#1907C=E5PU5N+'.;@Y10*O
ME?/;*<?/H0H%[R&9+-I#>8FE&CRB&)IA&YRX)X-15Z+/M)WS6K8(,FO-GR>7
M0X@=4C`CU9,AXPCU#$:U,5\7*B='[%>_,FZVNENNTV?*+';:^IHZ^S,;1UM%
M^7-AFRKAZN@=]O?F32[K5VO=K/E%=N=#3UM#>&#K:.LS-EQRYDQ]?5K+N[6R
MN)0^5SHXY-I.E6$AD=M11D:!AI92D:%I"N<C<<,7+^'KA/8KVXI=U]Y-UVFS
MFUVYT.P:.OLS!UM'6?ES8Y<RX>OKY13X_*^2@G67W^[C-#>V@I<_9\AC!B;V
M2R4AI6U"N4>=5R-\$Z%/JYWS6LH)\^A-@2>73(AM(CPDTI,=Y`DTS#<U<%\'
M(J=?^XO^]>CRY9_FY%BQ0DD29,@G,@QX\<+%(8YS$5HQ!$-JN<YRHC43H4"K
MY7SVRG'SZ$*!>\AF2S:0WF)I1H\HAB:81N<N">#45>N<3^0SOF36A!QJ#L)M
MS)Y1#&&P+S7B(?=),UXVCF$@D.WR+G42O3ZN;KD<GE7*;ZPIJGA%O<26VEI:
MVL>*R!84Q#3&1"%E*XP8JDPR,4F"JB>OK9<4EW%#4/F`!2U5,\@+N<;,6.`D
MN77>_'F3W2?]D$18[5R-1"/9JOK^16]CSV'!7;SAR95U.LHD?`D10,NX2S9H
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MBM0@W.P=F:UA.S`FV58.(:*21QJ^A.?'$S.Z?M]A9"255!L$F*\NV6.0J$1V
M;'*Y!D^9'RVX=*-/F-9.Y/#IH\DT6(D84>,^57V,6UG6&V<)$>YLI')'\&"<
MYB->SFE.4)[#CM:2Q">'L21[GCA=*7)S3E>-2!KXN>7&5I'M5%*U@W.,CD'0
M+,-V85D>X;7HJ-CK9R(L>$281&HBF,V+%:QF=7:2*[)EU'YO?Q9.37FC)O\`
M++W00;=TGMU<'3:V.W8QY*ZJMU,TAY,"/&@\`<?@.PG3(=P:$S`:[B76TUA:
M1H68QXP1;\T)`ZCGHT6?.N.&"RN+<C=VZDN)BQIZVA)<3[NW<-IP,,2.]%#%
MW1D;&F:C!JS*-Y"-8!47B?V[\-7/7+/L+XEINN??JM^T?7`?UI_9SJ324D"A
ME195D:T(2TBV!I"2#18<1S&.B6D(:!0<)N"957%5\?P5'?8=/%[+O]KVF/-!
MG[CLM;7WEA.S9=BS+ER^M<<?H^2O[Q_B6+U7\9JZWC1X-;N]`L^':%ENWDZ3
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M2>01IFTJY36[=[MMN@/`-C!QFXSWE*N08V"ZH;NDY!?55!-K>UD'3VMO!CCN
M(DJ7+<^8V(X,)AIT*6W17,I2)&)X8#Z#Q;YIJ:5(BA<.197%;W^LNX\:4$U:
MV8"/%E2G6045$Q*`B/VVL\VJ_#J?8\,J)E'22M,K8$QT=,DM[<TQ\6'%4H:V
M&XR^2.A3-;ABU6,5H1<4JYXM"=6\:HH$T&<9=&7#JXL>2+4"\@2:9AJF+7*U
M?H7K@WZ8\9_/4+T<3^W?AJYZ=SRFC&?67!OZPC!&CMBU-GA'"&:J@R$0-X15
M4CWL7"9BKBJZ0-B<3^W?AJYZY9]A?$M-US[]5OVCZX#^M/[.=7'Z8V'YEX_U
MP']:?V<Z^2O[Q_B6+U2<9M*WDIYU;W+7+`AU98CMY;SYX])\BXBF7`,IJ+BQ
M/-C^/K\C\Q_Z?2_^0=<Y_0[DWYEF]<3^W?AJYZY9]A?$M-US?C*&T#67`IVT
M*I-(;;"'R+C,^NW+]O*<D-9T4:&RL5^EFR^;!>GV%A5&*/1DT-]7D8^/9Q([
MID8DK;B,X*#LH4J"WV1L$=E<-5&KM1EQ2<;IKC?74.14F-=AA1XD6OGQS1II
MQI`M)ACS$"_*)JY&(YV=RKDTW\OY66-,;5<=AP&1Y[-,<0MW.OJ2$D!^HUSY
M.6JG'*Y!8*)VDKU1'M:^17C>()CK&8DDC,ZA"V=$DR<N'F<JCC>#<41SD3%4
M]:=NMXSP%17#CR_.Z)/T\F+XQW-1"8L(U5^E%7!R-=Y>G#N6M@O:W,V0%AS`
M,N=?)HL88P7(Q4^EZ.P7Q;X(K3QC"D!?CD,`C"B?E<K'92#5S797-5/Q^BX)
M:634;""V/,AU\W)<(6PCD=$BQVQ9`)L6=,"US@N1PE:UJDSM:Q7M5].^ZL[=
M]@>;!E"#(6^E'$5\Q+%1Q#S9+)^`]9ZL*16.15SKAFZAS=O*A[R+'E;2<+;S
M8NX$PNWF`S/T90,V4C,5RN14Z;`YC.XT"#98Y(7)I-6*)/V9`&=EC6CT#*VI
ME$[U+D=E7\'3#1$OJ,;0M&L2KM6ECD>CR.60]UW$N)6LY'HU<I$'@U/+CBJQ
MI<*F[C:Q?$=O=E[C+0B2VS`21QU:.JB3(CQL01@1Q%:UOUL5<KH](:UK17,L
M*R(E22=%99RH[4.YQX\!Q4E&"U(I/,UJI[-W\5>H-I`XSH3JV9&GPC]ZY"71
MEPS,D1BZ9K8@2:9AHN#FJU?I3T,O>"CIYEK39O>JGE,^[V/<(TJ'[</>9T=N
MYCN*UNHSQP56^*>$RFN88;"LL`J"7$.BY",Q1S51S5:01A$:CQD8K2#(U'-5
M'(B]"Y;'K8?'S56?);S[^U9$B;X;ZUVJZTMGP4UVS-),Z?6>F'FPZET5[$WU
M5.T-U%UY,;5VTD,P/MH9H\AF21'8[RO3'#!?#J?]UJGM?=-KOO?K*;K[+<[;
M\HS)>GI[LGU,N.;QQP3J+/YZ"&L&DUM";/N)E-$A=R)#"35DQ["`'WDP`M34
M5?-@C?7XI&X=&#'IK$W>!NCV$JSCRWRXL8;9@)<N7,4@3Q8XLN1^FJ>*>OJ!
M]Z:GNG:]UL??K*%H;W;;G\G3(FIJ;0?U\V&7PPQ7JJA<@K8</CG%=]VY\^_M
M:^)6]\G"++U9[[8#G[R<K,-8CL'*C688X=`EQ.-!E1901R(TF/R+D1H\B.9B
M$"<!AW3AE"4;D<US55'(O7]D_P"?>2_TSTO&[B3#_K+#LH`ZLTUL67;1-HYM
MH*$-A@S#:,,V)%#YA-7-BGKZB7M%Q[8VL'7VLKNUY)TMS&-#-[&992([\\>0
M]OF8N&.*>/4NBO8F^JIVANHNO)C:NVDAF!]M#-'D,R2(['>5Z8X8+X=6LG@X
M:UMS""^GN6PN0S;>1`864TCX<^)(M)R0C.E5G\-C28B<G\;HLF\HP]S($PTN
M(#R5]FCR1PQAR#&C.8.Q-#''9H;MD@8\N&7*KD44F0?DMJ$>?/`GV<4<0^<;
MV-U7U=;6SDTG.SID,SS-3'%N*+(&$_""\(B&2/+&,E"_BL60Z4"6T$AK56I"
M9TZ4,F5V"ZI&N^LY/0Z)8Q`S([L?9F8CLCE8\>J)WUP&:PBY7L5'MQ\%Z)(X
MS,U6)F?V>R?]'M7Z4"P];?!&"$,WE3Q<\O4@CZ?D58^.%5F3:\<@L,47*V01
M[[.O<X#XXV-1Q,'*C5;X^+>ECIR.T5B%61Y32DDJ33R9$F*C9.DJ?Z/4TLWC
MACX]7%E'AEDSBOG75B*,`NE$$8SSRI.5''(R''*;Q<Y<&HJ8N_#6<]N9,&3'
M&U9E-7@<&<JS<QX[9-BY1DCQR5RMU!#$Y2CD95<HGA4;NOEA-D,XT0(?OKG9
MR^NL+7CJZD&E$WN$"KC3)Q\'/]ED&[*?(Y<&HJ]%`KYDB/'Y+=!@33%EOK;"
M(S;>^\?#-@5\B'3ED:GLW-5VZ0SG97N<(?7R[_0Z;_PG.?1R_MF\W&SAZFQU
MM;M_=8'=L^AY]GVK6W&/DV^?/Y,>N'3OE1'LH$(/%+$G-86)(,$$,=:ROK8Y
MP2CZ]A9#LR1][IND`*9`G:YY$.7T<L^POB6FZG_=:V[IVO:[[W&RA:&]W.V_
M*,.)J:FT)]3-AE\<,4]'RHM.9QM3A\"9RQ+8YH4Z;7LEDK:^131I@X(3N-N9
MT+%`JUS3,&_,UPT)USPG&@60OEO+OHTCAA+,;&/E2&QRQ.0GAN*B69JUIXH!
M@<?%=,>5WMVR/1\M[2]C0R4D#[[(0]Q"M)O'V79*:'(XS&NAU`3RS0Y-O"8K
MPM:Y3!&3%KF(_KDVVV>W^_MSH=N[AV_1[71:6Q[M_P`UV>3#3W/O&3#4\^/H
M^2O[Q_AJ+Z.5Q.-`-*MI5;MV1HXPFD2()I`!W(`!,CM4Q:9QVM:Q%,Y5]E[3
M+UP"%\MJODJR(O&K=O(K5IRP0I&+#-(:'F$18)V74QEJY,2B)'B"D$CM&0S&
M!$+KE`);K(<71KI$DM16,N)P8\.YKIACLKR3ZP90@&!7F<XXT$%'$\<N"_-.
MK&?ATJJL>'</%+Y&&JY6G%ZB773H_&8K)L(O&AVKN2VC)K[`<@87-WXM;!4U
M-+T^Q@:_^]"'_*3KVT30_P!>,G\E/[\__]H`"`$!`P$_(6B`,,@3<C-'*7!1
MO!D@BSL2JF%MQB(<);2M:XIE,PA!JU!"BUD25)2%VE7.;R(C!(#ZF`'[^LHL
MYQ&-_,L<**J5,-C+[&,,"<<1-HP.(]\UYD)SF'\D]=5,\!59<6TL0"!4HBLD
MS:(T$NR##926Y1#SOBBV"3]I7-G"]$;>Z>3WE_R5=`/NF!9[6]YZNP'U3*$_
M"E!.@]XUJ_"E!.@]HU+%#1<5P09!=5J_P)81H/:-:_,??0S*W/YI,3WM[SU=
M@/NF1.,^`GZK#*&*5`GO+_DJZ`?=,"RC;H;CU:+=O!!WZK`B28FC;BA4VS>C
MN)J<25>6?[>HT*V(Q*JYKC'W8T`YF0Q-F1:\'G:W)=SKOD`-N6U#:MJ;<\IQ
MXT[)T!!E@`8E^TTJNQH2K*89=<U4/M!IW9?27^L21_[.=B,TZPY+8=C>8[/)
MAI*LI^"QQ1$O6>HV6:S'])Z4TLZ-.LF"E<$\EITSM3OZ#W9K1T>$#ALO4<*/
MVKT\;.,,[L`JEJ)8--V!"/R9H-GM7M#@?\*IS#?[3P&VTR`K2F'@B<EAA]!<
M8;+XGV5N7BUZ3,OE7]FO<!ZV#3P,60GGL3^&]BL6$CI0!Y.^PJN#T4NJ*[-"
M/5N+$A!H^(/+\@OB(3B/D!5:`IB<)2D(A48E=-Q3/C[CQBP"N;**KX5_)J7`
M>MH4^@N-64`XNMV+##]"@!AG>&Y_QNGL/_M/`+*7HAEQAO%%?&NV[GF*T&>)
M9L"T[H#'*%I7IT9P1P5;C8VCC,_C<>$.5G2L*%DER4OP2'UD-5TK_(DN`?$G
M,0<0\K9+!>43\4I*13@)LX:'#F>?YQU"T,US+IP2LQ[S_P!GR=+S0(:GD#O$
M?':U?8FT(#AK$H(PPV+EROJKW=%0U^HQW.MV(4RI4RZ/@W]@O<!ZTA9Q^;"!
M'=ZA%A+(`*CME(2?3SBUO.JWMH)_WX"=F)!1(_E0^K_UQ!_8CO-=U!X%D&$4
MBA6&8Z"'DOY4/J_]\0>,&RY/WSSX`-`3]5AE#%(H\#=W`;`&("]"L,?\V`A9
MJ04`G_?@)V8D%$C0DA%"$65!&N!&2`*DC8)`&N5^)4EY57>7`F1K%9H0]ADM
M5898NGX0ZRK:0DP[:*K1TN\.+9`S(Z2JX3)!#,H)Q%&R)HU4-F![56C1SR!G
M.-&#J-?DG^A&=P8GAQB!1?VXZHD:6140"O49]_TT19+[<0-H&'6EQ9ER%6(W
MY4/J_P#?$$P-@J$LJY8,FBIOHH(4Q\02H2AX`$W-#N#@7IT\1%@GU^BW7X8I
M8("Y&DQ&Y-I/%UJL%M3!)*@BMD3#J4OZ`R?$H$>;?1?MJ.U0\_V;0_:\?XM^
M\__:``@!`@,!/R$)B.1C&CTL,<LF!:D/-:WI3@YU@4)-257X?.#-_2OM$5H'
M(3$J8E3!*XQ,3$Q&$[F)B8F)B,J8E1]%B6/'432!W[^/,\=/YG*G#,,J'#PQ
MU#?)4JIW*E<.H;X>+8$D*$Z5`8;-B@L]Z+8(.Y5_:A/1>VL;*_LB-=6,-6BG
ML/NHI@N\#"$KQZ74&.H;Y'AW$E<.H;C',K@#*,F:%E=ME&+:%#(_(ZQD8=`.
MRZ!"!LH[L@"7MH&&#-1KF6D0HS4TTB-(C[E<4K!9R3X9M+D(&8:650L(J@4-
M$75LY3'M`TX2^DZ3OBV7Q;QGBWU6RV6\7QF7+Y3+_0NFDL=T+5`Z8YOI_G*-
M'*`S;ANI(U]!&;47K9HF!H&P[*KLP_,@J-Z]P%$#IEA2FKM9Y,]36B-5`KT*
M(1XZX-SK/!ODCP1XZX)G@W_`O__:``@!`P,!/R&YF$0NT`(S4;2UJED+D-I,
MH'<U\G:*)U+MT>VPM!555F\0@-"TCL?#^_\`(TMVN^ZLS@R4XK5D8=B>1KIV
M5[%8U&M:_K)Y$^3/GR#^ZP.4(['HR``%<(Z4E%F$%W0,6Y_)CP"T)B4$_NC,
MJIIGZ+"I::Z:^[W5?+X<2C<$<G%[P7LDS(I*WP;*T*$TB5,5;TO,^]5I:PY@
M818-?NJ:/=_,/N9F9_':Z.@..UEU;FT*#S3JM^(:A_>?SK_-08>&LTS`>5#[
M94`\7%,]CRFX%.U3_&?_V@`,`P$``A$#$0``$,U9@);97F?]>;66:>`$L,>B
M/Z+;[;J/X(P!X">N*Z+5:5J*;V81VU@```LE@`HAMA*P0&@@"!AL%@!B!P`^
M`````````````/_:``@!`0,!/Q`;?&197K=`5^9;;:7JBEK"HH03YNK.:BU%
M(K1R9-K=O.J9;"CZS>&&/E;`,33;>$,RK,B(CSU[?)6O#H*QP=0J!:<?HW((
MV4$G6^24)Z&A^T3[-1',"T;^ZG'5]'.CL4+O=3=I&MRLL_N$"/\`K@Y0)C[(
M8(<RV1GZ^A^KH_LMF?<T/Y=#]EMSB)_-O@#1/YM\`8BJ@$8M_B=A/`HWMO@#
M??$8CAG/%K8^IH?RZ'[+9D*+XPH[W^`I@GU]#]71_9;,Q/K%)`K[LWJ)SOIG
MM5L)XJ:91X+&,L<@-QLNE2:W?<-O\)E"7OBW&F%@52BEEAQ^BU)`*U27/445
M2RI%*\')B[PTS=Y&$0Q^SAZ+[\.@Q5^7*P^EQ"'&##:=S,:)^A+XOD.\LZ6=
MM=4/2[OH>^7!6XN?^V,E:GSQX(F-MNH6O$2[%F]]=&-4V,6,GJ2P0^/5UTG-
MY:\]!#4HJJ*!`#%A:\UKS&\/N[(157U8&4XT>;9X7M+@QM']%PQ]-^**M^P!
MT?GKJFY\_3BW^H7\V["%,L,I`CN@Y,*'E=R_13TL*@=U:^C)].?$`_F]GL;E
M1O\`Z3F/H#PX($@<"7,[M9_HG1F0Q0>)PSB<4(N-*L/O<^_EC](OYMVG/XI=
M_P#]`:IZZ;0R1155KJKZO#*<Z/-L_I.O\45\L6*XSGN[EQ1)W*5@-2_`..\7
MNT>>VCD:-W'>=-[%)#2S0CV?/#'"FWT&Q12@HUW@KE=5I:15O&[F$@2>_6+3
M)!)]TI`A:,"`'O833@8*9++7N8UH67^.6RTA.^1?DO,5T1FRV^0Y[J+02^K/
ME-@O'J[UW77!+[(WW(K2UW\@6?M1[Y4)^;=I/ZUL.-;J6D<=C_\`Y0\_O$9?
MYN/S)@Z5FHF<%"L"UX`?!PPC`GW-[]R0^ESB8<7?2=/:0;<./#AA&!/ZM_78
MJU<]1(%T8,=[_`4P6%?"VJ+X1_I0;@HUX6O`#XH5@6O`#Y4#WDQO\`9`/#A?
M#<F>YQ*DON(/9W*IVP3ECW6C\?'71<'^>!TT]R=?&N"0-BQ<U6GV&N)8<C/!
M"HH;L$@EGRKR`AMX%Q@@$'OG'F)Q>AB$;1H?PJ!S`3&,D%9Q&'?O03?/Y]'Z
M7*/)N,52D;RD]._UE[:3!0<,(P)X5'OKZ2^[[@!VLOEY\.NUQ>E1^OJF^F75
M7H[L6I.5%OH)3GO^)3*\"XQ9-1LI80%"PX?5SZ`50]!C\@G#P@$@=4!;'5BW
MVX)83;[3YLX<;HSA7Q86?T_=_P#_V@`(`0(#`3\0M+=13U#^U-O8H0>C0$91
M<,2!"`SBV#*5;C0.M2B#0;A:$97YJ$1*1,(CD1PCKFQ]HUPQ#DE(@KJ-&I1B
M4U*]D^DH;J4M5#3B$;N`6GTGUGTE>R;%5"5C=P`9F>,1-GB>'H]W9:[.,T)2
M44B.*NK)76,USA0AEP"BZ7(6"ZFFQL$1\(B73FD&S@C<3)%&ECIJ>_<5OM%H
MN"RS?-=)VB'+`:0VB5N)"X;/GFG9\QXKF:.RS0E<P+@R)*4A&(.09"Y<G:4I
MR)8@9%-(-I66D'IES,`.+XJ!*U^4MQPU<.XJ[@NL[CN.GFZGFND[3>=H;15N
M7AL^>:54^\%(,;8N:A+HD4&(*0R,6C,K*-!6K8(L$`1,'&]J,11<EBZAS[^@
MJLU`D%I%D3@::L5?"`48ND5BLW(F#"`(#@29QTA`\(.UD4+:1(7UQ*97?7(N
MC-9)9B#62*NX*:BKO<%-0LQODL[BG#!K)%6]01J7F;[OB^$S0L='`2+*@YEZ
M&SP6NMY024(S$$UT/5I-X0+(MB0U0!W#V119)6H\H;"`::J6Y`JFPR;`*Y8.
M5V3&G<3VK-^#?YY&[<I$WQ:FMSI>^-&MS?ZX-N*7F.#?([-[]`';*//[S__:
M``@!`P,!/Q!IJ91&+Z1@D0@BQ`QB.SD`$`$%O,-%1L@7`HF1I&2<"&5ZS@$`
MT@TB)2.1P_L']?/^MB`"QH.!L!*T!FBS#!`H$8*U%@*AB!!M8((>$!8`:`0_
M3(_I'+0"%`5HM:"_*H!VH&680_?7H0T?W:7.4$3ZI"BJK?@UOZEH7\D1A'F_
MT"R,S9H$*-M#1BVA0R`A88J]"P-TLK8C>-96,`L$]N'+FH,!OI@Z5(H1@EY9
M<9+:P-_X$`Z"%$"NN*_:URE=NA=-)8[`6D!>$AS4.VZ#Y=`M9M0Q6D]]\BGI
J%&AHF4C%:K:"QK0AOPBV6MQ?)7<[3.@$76T;;B+]VB"(Q?O3(]_Q7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>sig_jriley.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sig_jriley.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```"]0``"*@```HM```+=/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`*@!Y`P$1
M``(1`0,1`?_$`+X``0`#``,!```````````````'"`D$!0H&`0$`````````
M````````````$``"`@$#!`(#```````````%!@0'`Q`!"``@,`)@-18V%Q$`
M`@("``4`!`H&"P```````P0"!0$&$1(3%`<`$!46,"%!(C(C,S4V-R`Q45,T
M96%"8V0E1<76%Y<X$@$```````````````````!@$P$``@$#!`$%````````
M```!`!$A$"`Q,$!@0?!187&!D?_:``P#`0`"$0,1```!W\,X31X```````J>
M4<-*B:0```<,SE-!CZ`Q#)D)<(3):.G.:7A.&2(`?!%5R'#4@`K>1Z72!F<#
M14[P`$2D6F%IZ?@``1P<HHV=J7+)!!`A2(U8````!T1Y?3*(&OIZ?P?_V@`(
M`0$``04"ZN)\9:I;?.?>*3:0R)<*[6K5!LFNRDSP2)$>)'B\HT3)A%EA9R#U
MOQU-([%F,T<O8\J%QWL<;7ZDK@6`]QBJ6?'!,5[L0I*PLN&Y"IS$-S8BA3T/
MZM0N0<6*-8A376AL9BX]LVI^GZN9\8+CS3RR8TKI]JU("R+&8?9ICC847/V;
MHRM^7WE)#Q*A_FG,GOW3E'V-LRR$<0>X"ZJNZ$<CU';W!MJJSZM%HUVE]9\[
MA>[CXBGUEO?IVG&G7__:``@!`@`!!0+Y!__:``@!`P`!!0+Y!__:``@!`@(&
M/P)!_]H`"`$#`@8_`D'_V@`(`0$!!C\"]-.V[BQ9^/K]E+6-FJ0Y!AE"P4'L
M3%>S6]XY(4B6XKB9CX&N&4\TH!S:C`G+GX>PU_8-Z\<6E/:KY6>19W#7^F4?
M'$X2C.%G`H&`%A$@BCE$H2QC.$HSCC.(>*KS?Z7;],FJ%C1M]#;HO^Q42E8`
M#5=QL%)Y0&9#MN4;&)8A`61RG@8R8@NO7UF^Z78V#9,!411VFC;<:-+Z(EUE
MWB&,27R8CC.?@3MMG"JJJ$C#++!(!777##)#'.8F8C$$0XYE*4LXQ'&/1.TL
MM<\BT.K/-,IK[M:ZIU-3(ROAS'2#95%A:E;F8Z!!1P`1<\^,\W+&,Y1!:4ME
M7W%8UU.VL:MQ>P18Z)B+FZ#:A"KEZ3`I0ERRSRSCG&?CQZG-F0U73_."A'K&
MT(ONUI;5N\.&MR'6RD0U@X_X^M^PB:+AG7E('8+DW)`<\`X2QY)\*5OC9@4Z
MQ29[OQC46^N.6E@C)V:=+M6K55U3V,58#EQE.2\^&,_5XE`L1VVMT"/C)I@Z
M69%:T7W3AL%5#J#Z-BJW20(RID#/)\<\9"3[,D9PE*$H^*?)/C317[T:C+>G
M[L#1*+V?O5"AB/6(WG%<7"&QU8I1PV*<L\>.)<TN893W#%-K4->V)P;QZNYK
M[/8H#I;@^"$3L4J@-ZG6C@@Y*)!KPB(,<1Q'&(Q]*O5/=&&A7Z`BU^W[W?X4
MOJM?$:X>:YW4$!74Y;);.9/$A9E(1)8HY#)DLLYQ#94`;IM^TT=+KZ(MQ+LI
M@8JO>MX:YJU'6:FOUBIIZ?*-7'KM=N:76PV/FXRA+.54A)NV]F[GF#5U?9Y;
MPI$@QM6)Y6#E>DL@GU.,YD+'FSP@/$RRC"1*JPKJQ=%D)V*1U6^BR^V-+ML.
M^T*5NNK#)9A-N')E4MA#A]K(.<PQ/U['2J3"-JXH;BK6(Q*<5X,6%>PH&9Y#
M&4D0Q(7'-F,99X?)GTK]5?57A<:=5@T3<M5L(3,PI.J7G2P]IH/IJ3RG?()=
M7$9"D+YQ`<TYA)P'NM&<Z?A_:;:"N^ZHI6M/J:C;O+D%7[C0@4X1JJHC@@@=
M'CXL0E$8A&SE02WKL(7.A:P<MJQEM^P6JEJNY9:FUAPK,KRJBE<1.PQCB6<3
MXD7C+$^.)2QFNOZ34.RMJIF#B#?M_:&>@P/Z!.@W='6+P_9.$L>O=9VVW:U3
MV?O_`.0;"\4;8K%;XI1[+9\N(U2K;=S;X@M#$5Y8%UBPX8B/'Q8]*+<"Z<WK
MNG6MIGQY776P"N?:TQV;R+:FR.:F"G":LJ+:P1P@IEEP1,S9&>4.3YF3-"#Q
M;8YL%;,0K+<A28,UA7#+,RG@B$[,\B!&6`AYLXA&./T8;["KZ&V1KY59;91V
MQ2R[7RCR]M:I*-AKK>$,8AR]T(V89$+,>&1#Y?(9;V())2UBQ7#AE3+@_:[@
M^TUZ40Q"?,3POSK9$7A]07E)S1Y>;'WCO_\`VPC_`+R_3]YLZMKF=CY\%]X,
MT=9F[ZD085B3VKVW?<\5L=/CS\>3YOZO1_7=B0%95-D'I,KE^3^L,X"8X$7:
M7)C$QDAG$X3QC./3GU.W_P"8M1#QS[K[@Z-#>418P3/+5[9T^VM>)B\\^Z'Q
M@$<0KBX_'Z(([]2;;XJN'QI8`MNU!8I5SC+$^BUBNMHKYC*OKSYQ@C3@D1XC
M/$L\/G<K.-:V;7]ARET>\Q1W-=;=IW'5[?N>P98Z'7Z,^3FX<W+GA^K/K<CL
MVY4%6TA$$VJN3XF;P<6NET,QH4LLW1NI`\9_,!+ZO//]'&<^E$,5&_3^`J=X
M-RXY<!A6L>36*\:MG3?X+9JE<>U!YLP"#$1>*K*L2SF7#.`A!\%8_P`#_`M_
M>GW9]@3[Q_N/[W^SX^A?_*/W@C^4/XQ^E/[+^7_O_P"CAZZK\@/Q^C^/OS2_
MR+\%?Z=_,>IZ_P#_V@`(`0$#`3\AF#P&^UJ$*34["??R&J9A,9%AG_VS;`+@
MCASOZM^\L7794^G1=`3-5AE#%*@3$9\@EFO&M;`/U=PW<DMX*0):?6M?P`Q5
M((NJOY0?G5?:B(8*ZGBPBJ1F/@]U#C,@&:RH,DLP$0&>D(2P`D8:9^Z(`U];
MJNI7'\W93%T'W48IBIPGS:8X$1U*N!V63L#U.%24PT$3EI,0-GV!??;$!9(@
M2#-`?]C9ZUB\*E83A7F*U,/>">I_89YC[-0N$,]#&4Y'#+&#>J.TY`=49\QP
M]9*6IHIE;7\PQ,1'1-4A.0L=PY*@&(@*+Z&<JKYA&Z%UH8Q^Q'G4+10BF@#"
ML2"KA8B8772#6NIIO"(,2RUAN0RV5J;Q4BPK\R;!I?\`7KRKX`&-<HD]&P`1
M>R=FK/N#DS_\?Z?_V@`(`0(#`3\A\@__V@`(`0,#`3\A\@__V@`,`P$``A$#
M$0``$````````!(``````)`))(`!(```(```)```!)`!```````!`/_:``@!
M`0,!/Q"55^RB&[%&2*#++<?SX9!"X#*":EC?-SK8-KJHYVA@,L/\+HHI!;CO
M>X"F"!Q7X-6LT#WC:VRH09%@$$6]!_,O-6/;"1VJ>U7]&T[*%0,BQ:S$H/$L
MGYJ("[]'CM=KW_V_2EXR&WW"MR@>4<T1B%/WDC`HWO").Y@17!2]/1?K"TQ_
M'E+Q[!R,\`1@*&R+A@PS[(N\8%S'#!\$>/K$&1VZW1YP]`W?2)S[YRM,L\_1
M\K9=<@X"CI0<T!B&C@=0*_BLXE,"\&J/[-Y=L%5Z0OI,IW/<L;Q[K8L&$_0]
M+@4(&V2,XW%M8(22FRU:D0<B@IE&O"(H\@7XQX_J.HX%5<JB=GJ4C@<$U2]<
MABHO8`"*1*#[!$13C"Z12"O`@$7+'\_@_P#35?_:``@!`@,!/Q#R#__:``@!
)`P,!/Q#R#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
